Aska Licenses Rifaximin Rights From Italy's Alfa Wessermann
This article was originally published in PharmAsia News
Executive Summary
Aska Pharmaceutical signed a license deal and obtained exclusive rights to develop and market non-systemic antibiotic rifaximin in Japan from Italian firm Alfa Wessermann